Namenda
Product Images NDC 68151-5817

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Namenda (NDC 68151-5817). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (68151 5817)

Namenda XR (Memantine HCl) Extended Release 28 mg capsule label showing the manufacturing details including manufacturer Forest, lot number 115304, and expiration date 07/16. The label also includes the labeler Carilion Materials Management and NDC 68151-5817 with a barcode.*

FDA Label Image

Molecular Formula (Nam00 0006 01)

Chemical structure diagram of the active ingredient for Namenda XR, showing a bicyclic amine with an attached hydrochloride group. The structure includes methyl groups and is drawn with standard chemical notation.*

FDA Label Image

Graph (Nam00 0006 02)

A line graph comparing the mean change from baseline in SIB score over 24 weeks of treatment for Namenda XR 28 mg/Acetylcholinesterase inhibitor (AChEI) versus placebo/AChEI. The y-axis shows mean change (± SEM) from baseline, and the x-axis represents weeks of treatment, indicating clinical improvement or decline.*

FDA Label Image

Graph (Nam00 0006 03)

A cumulative percentage of patients chart showing the change in SIB (Severe Impairment Battery) score from baseline. The graph compares Namenda XR 28 mg/AChEI against Placebo/AChEI with the x-axis representing SIB change from baseline and the y-axis showing cumulative percentage of patients.*

FDA Label Image

Graph (Nam00 0006 04)

A line graph showing the mean CIBIC-Plus score over 24 weeks of treatment comparing NAMENDA XR 28 mg/AChEI to placebo/AChEI. The y-axis represents the mean score with clinical improvement and decline marked, and the x-axis represents weeks of treatment. NAMENDA XR shows less decline in scores compared to placebo over time.*

FDA Label Image

Graph (Nam00 0006 05)

A bar graph comparing the percentage of patients with different CIBIC Plus Ratings between Namenda XR 28 mg/AChEI and Placebo/AChEI groups. The ratings on the x-axis include categories from marked improvement to marked worsening, with the y-axis showing the percentage of patients. The highest percentages are observed in the 'No Change' category for both groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.